0
Original Research |

COPD Prevalence in Southeastern Kentucky: The Burden of Lung Disease Study

Jennifer N. Methvin, MPH; David M. Mannino, MD, FCCP*; Baretta R. Casey, MD
Author and Funding Information

*From the University of Kentucky College of Public Health (Ms. Methvin), Lexington; Division of Pulmonary and Critical Care Medicine (Dr. Mannino), University of Kentucky College of Medicine, Lexington; and Department of Family Medicine (Dr. Casey), Center for Rural Health, University of Kentucky, Hazard, KY.

Correspondence to: David M. Mannino, MD, FCCP, Associate Professor, Director, Pulmonary Epidemiology Research Laboratory, University of Kentucky College of Public Health, 121 Washington Ave, Suite 220, 740 S Limestone, K 528, Lexington, KY 40536; e-mail: Dmannino@uky.edu

*GOLD classifications are defined in the “Materials and Methods” section.

*Data are presented as No. of patients (weighted percentage) unless otherwise indicated. GOLD classifications are defined in the “Materials and Methods” section.

*Adjusted for age, sex, education, smoking status, and BMI. GOLD classifications are defined in the “Materials and Methods” section.

This research was conducted at the University of Kentucky.

Dr. Mannino has received research grants from GlaxoSmithKline, Pfizer, and Novartis, and serves as a consultant to GlaxoSmithKline, Pfizer, Boehringer-Ingelheim, Astra-Zeneca, Dey, Sepracor, and Novartis. Ms. Methvin and Dr. Casey have no conflicts of interest to disclose.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).


This research was conducted at the University of Kentucky.

This research was conducted at the University of Kentucky.

Dr. Mannino has received research grants from GlaxoSmithKline, Pfizer, and Novartis, and serves as a consultant to GlaxoSmithKline, Pfizer, Boehringer-Ingelheim, Astra-Zeneca, Dey, Sepracor, and Novartis. Ms. Methvin and Dr. Casey have no conflicts of interest to disclose.

Dr. Mannino has received research grants from GlaxoSmithKline, Pfizer, and Novartis, and serves as a consultant to GlaxoSmithKline, Pfizer, Boehringer-Ingelheim, Astra-Zeneca, Dey, Sepracor, and Novartis. Ms. Methvin and Dr. Casey have no conflicts of interest to disclose.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).


Chest. 2009;135(1):102-107. doi:10.1378/chest.08-1315
Text Size: A A A
Published online

Background:  The Burden of Obstructive Lung Disease (BOLD) initiative provides a standardized way of measuring the prevalence of COPD.

Methods:  We used the BOLD survey to estimate the prevalence of COPD in adults aged ≥ 40 years in a target population of 325,000 in Southeastern Kentucky. Testing was done at survey centers and homes and included questionnaires on respiratory symptoms, risk factors for COPD, and health status. Postbronchodilator spirometry was used to classify subjects. We determined the prevalence of COPD along with the relation of COPD and comorbid disease and physical and mental quality of life measures.

Results:  The final study population was 508, with a participation response rate of 25.2%. Overall, 19.6% of subjects met criteria for Global Initiative for Chronic Obstructive Lung Disease stage 1 or higher COPD, and an additional 17.6% met criteria for restriction. Diabetes, heart disease, and hypertension were significantly increased in subjects with restriction. Physical quality of life was significantly decreased in all respiratory impairment categories, compared to normal subjects, whereas mental quality of life measures were not affected.

Conclusions:  In this population, respiratory impairment is highly prevalent and associated with comorbid disease and physical, but not mental, dysfunction.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543